Haemonetics Corp (HAE)
Industry Medical Devices
This stock can be held in an Investment ISA and an Investment Account
Sell
$82.07
Buy
$84.50
$-0.96 (-1.14%)
Prices updated at 12 Dec 2025, 21:18 EST
| Prices minimum 15 mins delay
Prices in USD
Haemonetics Corp is a health care company. It provides products enabling in the processing, handling and analysis of blood and portfolio of integrated devices and information management tools to improve clinical outcomes.
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
- Key stats
- Price
- Fair value
- Dividends
- News
- Financials
- Valuation
- Profile
Income statement
Year | 2024 | 2025 |
|---|---|---|
| 1,309m | 1,361m | |
| 692m | 749m | |
| 173m | 201m | |
| 13.24 | 14.78 | |
| 118m | 168m | |
| 262m | 337m | |
| Sales, General and administrative | 432m | 437m |
| Interest expenses | 13m | 10m |
| Provision for income taxes | 34m | 44m |
| Operating expenses | 518m | 548m |
| Income before taxes | 152m | 212m |
| Net income available to common shareholders | 118m | 168m |
| 2.56 | 3.43 | |
| Net interest income | -13m | -10m |
| Advertising and promotion | - | - |
| Net investment income, net | - | - |
| Realised capital gains (losses), net | - | - |
| Total benefits, claims and expenses | - | - |
| Earnings per share (diluted) | 2.54 | 3.42 |
| Free cash flow per share | 0.3958 | 3.7888 |
| Book value/share | 17.4948 | 18.8487 |
| Debt equity ratio | 0.830831 | 1.122307 |
Balance sheet
Year | 2024 | 2025 |
|---|---|---|
| Current assets | 769m | 935m |
| Current liabilities | 300m | 578m |
| Total capital | 1,758m | 1,742m |
| Total debt | 808m | 1,225m |
| Total equity | 960m | 821m |
| Total non current liabilities | - | - |
| Loans | 798m | 921m |
| Total assets | 2,196m | 2,451m |
| Total liabilities | - | - |
| Cash and cash equivalents | 179m | 307m |
| Common stock | 51m | 48m |
Cash flow
Year | 2024 | 2025 |
|---|---|---|
| Cash at beginning of period | 284m | 179m |
| Cash dividends paid | - | - |
| 115m | 142m | |
| Investments (gains) losses | -322m | -162m |
| 179m | 307m | |
| Net income | - | - |
| 182m | 182m | |
| -66m | -39m |
The figures shown in the tables are quoted in the currency of the stock selected.
Please note that past performance is not a reliable indicator of future returns. Please use the interactive graph for benchmark comparison.